Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets

Deepthi | Myequity news | Date : 12-10-2018 11:40:00 IST

Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin HydrochlorideTablets (US RLD —Jentadueto@Tablets), 2.5 mg/500 mg, 2.5 mg / 850 mg and 2.5mg / 1,000mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. It is used along with diet and exercise to improve control of blood sugar levels in adults with type2 diabetes mellitus.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally.

More from Myequity